(Total Views: 474)
Posted On: 01/26/2021 12:39:18 PM
Post# of 148908
Publicity after approval
Lots of talk (understandably) about long wait for trial results. I thought it would be interesting to think about the amount of publicity that is likely to come after approval. I doubt that we fully appreciate the current lack of knowledge about Leronlimab in both the public and medical professionals (with a few exceptions). Two examples follow.
The NYT keeps a list entitled "Coronavirus Drug and Treatment Tracker". It was last updated on 1/21/2021 (see link). This is their intro to the list:
"Below is an updated list of 22 of the most-talked-about treatments for the coronavirus. While some are accumulating evidence that they’re effective, most are still at early stages of research. We also included a warning about a few that are just bunk."
There is evidence that they did considerable unbiased research/legwork in the development of this list. As an example, here is an excerpt from their discussion of Remdesivir:
"Yet many experts remained skeptical of remdesivir’s benefits. They pointed out, for example, that there’s no statistically significant evidence that remdesivir actually prevents deaths from Covid-19. And on Oct. 15 the World Health Organization cast more doubt on the drug when they released results of their own trial."
With regard to my point about a general lack of knowledge of Leronlimab, it did not make the list of 22 treatments.
https://www.nytimes.com/interactive/2020/scie...ments.html
There is an organization named CETF (Covid-19 Early Treatment Fund) whose mission is:
"What is the goal of the COVID-19 Early Treatment Fund?
We're on a mission to find an existing drug or drug combination that, when given early, reduces hospitalization and fatality rates by 75% or more. We’re doing this by funding clinical trials of repurposed drugs that could lead to effective early treatments for COVID-19."
They have a scientific advisory board composed of 13 MDs and/or PhDs who have expertise in areas like infectious disease, virology, pathology, etc. They have a list of about 17 "promising drugs" and are supporting/funding trials for a few. There are rather long discussions about some drugs, e.g., Ivermectin and Fluvoxamine. Leronlimab is at least briefly mentioned:
"Leronlimab is an investigational CCR5 antagonist in late stage development to treat triple negative breast cancer. The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and shows promise for early treatment of COVID-19."
https://www.treatearly.org/promising-drugs
Lots of talk (understandably) about long wait for trial results. I thought it would be interesting to think about the amount of publicity that is likely to come after approval. I doubt that we fully appreciate the current lack of knowledge about Leronlimab in both the public and medical professionals (with a few exceptions). Two examples follow.
The NYT keeps a list entitled "Coronavirus Drug and Treatment Tracker". It was last updated on 1/21/2021 (see link). This is their intro to the list:
"Below is an updated list of 22 of the most-talked-about treatments for the coronavirus. While some are accumulating evidence that they’re effective, most are still at early stages of research. We also included a warning about a few that are just bunk."
There is evidence that they did considerable unbiased research/legwork in the development of this list. As an example, here is an excerpt from their discussion of Remdesivir:
"Yet many experts remained skeptical of remdesivir’s benefits. They pointed out, for example, that there’s no statistically significant evidence that remdesivir actually prevents deaths from Covid-19. And on Oct. 15 the World Health Organization cast more doubt on the drug when they released results of their own trial."
With regard to my point about a general lack of knowledge of Leronlimab, it did not make the list of 22 treatments.
https://www.nytimes.com/interactive/2020/scie...ments.html
There is an organization named CETF (Covid-19 Early Treatment Fund) whose mission is:
"What is the goal of the COVID-19 Early Treatment Fund?
We're on a mission to find an existing drug or drug combination that, when given early, reduces hospitalization and fatality rates by 75% or more. We’re doing this by funding clinical trials of repurposed drugs that could lead to effective early treatments for COVID-19."
They have a scientific advisory board composed of 13 MDs and/or PhDs who have expertise in areas like infectious disease, virology, pathology, etc. They have a list of about 17 "promising drugs" and are supporting/funding trials for a few. There are rather long discussions about some drugs, e.g., Ivermectin and Fluvoxamine. Leronlimab is at least briefly mentioned:
"Leronlimab is an investigational CCR5 antagonist in late stage development to treat triple negative breast cancer. The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and shows promise for early treatment of COVID-19."
https://www.treatearly.org/promising-drugs
(2)
(0)Scroll down for more posts ▼
